KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accumulated Expenses (2017 - 2026)

Moderna (MRNA) has disclosed Accumulated Expenses for 10 consecutive years, with $1.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 91.01% year-over-year to $1.9 billion; the TTM value through Mar 2026 reached $1.9 billion, up 91.01%, while the annual FY2025 figure was $1.4 billion, 2.87% down from the prior year.
  • Accumulated Expenses hit $1.9 billion in Q1 2026 for Moderna, up from $1.4 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.2 billion in Q3 2023 and bottomed at $987.0 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2023.
  • Year-over-year, Accumulated Expenses soared 113.55% in 2022 and then plummeted 38.13% in 2024.
  • Moderna's Accumulated Expenses stood at $2.1 billion in 2022, then fell by 14.42% to $1.8 billion in 2023, then fell by 20.63% to $1.4 billion in 2024, then dropped by 2.87% to $1.4 billion in 2025, then soared by 37.95% to $1.9 billion in 2026.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $1.9 billion, $1.4 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.